(Q32066328)

6 July 2017

1 reference

title

Glycogen phosphorylase inhibitors for treatment of type 2 diabetes mellitus (English)

1 reference

6 July 2017

1 reference

Treadway JL

1

1 reference

6 July 2017

Mendys P

series ordinal

2

1 reference

6 July 2017

Hoover DJ

series ordinal

3

1 reference

6 July 2017

language of work or name

English

0 references

publication date

1 March 2001

1 reference

Expert Opinion on Investigational Drugs

6 July 2017

1 reference

6 July 2017

10

1 reference

6 July 2017

3

1 reference

6 July 2017

439-454

1 reference

Reducing the burden of diabetes: managing cardiovascular disease

6 July 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.3.439

Cardiovascular risk profile in individuals with borderline glycemia: the effect of the 1997 American Diabetes Association diagnostic criteria and the 1998 World Health Organization Provisional Report

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.3.439

The effect of glycemic control on the incidence of macrovascular complications of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.3.439

Glycemic control and cardiovascular disease in type 2 diabetes: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.3.439

Pharmacologic therapy for type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.3.439

Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.3.439

Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.3.439

FDA approach to the regulation of drugs for diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.3.439

Surrogate end points, health outcomes, and the drug-approval process for the treatment of risk factors for cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.3.439

Pathogenesis of NIDDM. A balanced overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.3.439

Role of liver in pathophysiology of NIDDM

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.3.439

Glucose metabolism and the postprandial state

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.3.439

Contributions by kidney and liver to glucose production in the postabsorptive state and after 60 h of fasting.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.3.439

Influence of obesity and type 2 diabetes on gluconeogenesis and glucose output in humans: a quantitative study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.3.439

Contributions of gluconeogenesis to glucose production in the fasted state

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.3.439

Quantitation of hepatic glycogenolysis and gluconeogenesis in fasting humans with 13C NMR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.3.439

Hepatic gluconeogenic fluxes and glycogen turnover during fasting in humans. A stable isotope study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.3.439

The role of the liver in metabolic homeostasis: Implications for inborn errors of metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.3.439

The family of glycogen phosphorylases: structure and function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.3.439

Glucose analogue inhibitors of glycogen phosphorylase: the design of potential drugs for diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.3.439

Design of inhibitors of glycogen phosphorylase: a study of alpha- and beta-C-glucosides and 1-thio-beta-D-glucose compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.3.439

Ternary complex crystal structures of glycogen phosphorylase with the transition state analogue nojirimycin tetrazole and phosphate in the T and R states

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.3.439

The structure of glycogen phosphorylase b with an alkyldihydropyridine-dicarboxylic acid compound, a novel and potent inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.3.439

Allosteric inhibition of glycogen phosphorylaseaby the potential antidiabetic drug 3-isopropyl 4-(2-chlorophenyl)-1,4-dihydro-1-ethyl-2-methyl-pyridine-3,5,6-tricarboxylate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.3.439

Flavopiridol inhibits glycogen phosphorylase by binding at the inhibitor site

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.3.439

Discovery of a human liver glycogen phosphorylase inhibitor that lowers blood glucose in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.3.439

Indole-2-carboxamide inhibitors of human liver glycogen phosphorylase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.3.439

A new allosteric site in glycogen phosphorylase b as a target for drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.3.439

Human liver glycogen phosphorylase inhibitors bind at a new allosteric site

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.3.439

Effects of C-1-substituted glucose analogue on the activation states of glycogen synthase and glycogen phosphorylase in rat hepatocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.3.439

Identification of the separate domains in the hepatic glycogen-targeting subunit of protein phosphatase 1 that interact with phosphorylase a, glycogen and protein phosphatase 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.3.439

Specific features of glycogen metabolism in the liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.3.439

Glucose and glycogen utilisation in myocardial ischemia--changes in metabolism and consequences for the myocyte

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.3.439

A novel anti-diabetic drug, miglitol, markedly reduces myocardial infarct size in rabbits

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.3.439

Activation of human liver glycogen phosphorylase by alteration of the secondary structure and packing of the catalytic core

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.3.439

10.1517/13543784.10.3.439

21 January 2018

Identifiers

DOI

1 reference

6 July 2017

1 reference